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background: The clinical impact of 1st vs. 2nd generation drug-eluting stents (DES) on clinical outcomes among unselected groups of patients 
has been incompletely reported, particularly in relation to on-treatment platelet reactivity.
Methods: ADAPT-DES was an all-comers prospective, multicenter study of 8,582 patients successfully treated with DES. The clinical outcomes of 
2,331 patients treated with 1st generation (sirolimus- and paclitaxel-eluting) DES were compared with the outcomes of 5,493 patients treated 
with 2nd generation (everolimus-eluting and slow release zotarolimus-eluting) DES over 2-year follow-up. Fast release zotarolimus-eluting DES were 
excluded from the present analysis.
results: Baseline clinical and angiographic characteristics were similar between the groups, although patients treated with 1st generation DES 
more frequently had a prior history of CHF and hyperlipidemia, but less frequently presented with an acute coronary syndrome. On-clopidogrel 
platelet reactivity was similar between both the stent types. At 2-year follow-up, patients receiving 2nd generation DES had significantly lower rates 
of definite/probable stent thrombosis (0.9% vs 1.6%, p=0.003) and major bleeding (8.1% vs 9.8%, p=0.01) compared to those receiving 1st 
generation DES, but similar rates of death (3.7 vs. 4.1%, p=0.34), MI (4.7 vs. 4.4%, p=0.59), and target vessel failure (14.7% vs, 16.0%, p=0.16). In 
propensity-adjusted multivariable analysis (including adjustment for platelet reactivity), 2nd generation DES were independently associated with less 
stent thrombosis (HR [95%CI] = 0.49 [0.31-0.77], p=0.002), but not with bleeding (HR [95%CI] = 0.96 [0.81-1.44], p=0.63), MI (HR [95%CI] = 
1.14 [0.90-1.46 p=0.28), or mortality (HR [95%CI] = 0.86 [0.66-1.13 p=0.28).
conclusions: In this large observational study of patients undergoing percutaneous coronary intervention with DES, the use of 2nd generation DES 
was independently associated with less stent thrombosis at 2 years compared to 1st generation DES, independent of on-treatment platelet reactivity.
